103 related articles for article (PubMed ID: 25478729)
1. Alternation of adriamycin penetration kinetics in MCF-7 cells from 2D to 3D culture based on P-gp expression through the Chk2/p53/NF-κB pathway.
Lu M; Zhou F; Hao K; Liu J; Chen Q; Ni P; Zhou H; Wang G; Zhang J
Biochem Pharmacol; 2015 Jan; 93(2):210-20. PubMed ID: 25478729
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
Qi X; Chang Z; Song J; Gao G; Shen Z
Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
[TBL] [Abstract][Full Text] [Related]
3. Key role of nuclear factor-κB in the cellular pharmacokinetics of adriamycin in MCF-7/Adr cells: the potential mechanism for synergy with 20(S)-ginsenoside Rh2.
Zhang J; Lu M; Zhou F; Sun H; Hao G; Wu X; Wang G
Drug Metab Dispos; 2012 Oct; 40(10):1900-8. PubMed ID: 22745335
[TBL] [Abstract][Full Text] [Related]
4. LW-214, a newly synthesized flavonoid, induces intrinsic apoptosis pathway by down-regulating Trx-1 in MCF-7 human breast cells.
Pan D; Li W; Miao H; Yao J; Li Z; Wei L; Zhao L; Guo Q
Biochem Pharmacol; 2014 Feb; 87(4):598-610. PubMed ID: 24374359
[TBL] [Abstract][Full Text] [Related]
5. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
Wang Y; Miao H; Li W; Yao J; Sun Y; Li Z; Zhao L; Guo Q
Biochem Pharmacol; 2014 Aug; 90(3):212-25. PubMed ID: 24858801
[TBL] [Abstract][Full Text] [Related]
6. Impaired pentose phosphate pathway in the development of 3D MCF-7 cells mediated intracellular redox disturbance and multi-cellular resistance without drug induction.
Wang W; Cai Q; Zhou F; Liu J; Jin X; Ni P; Lu M; Wang G; Zhang J
Redox Biol; 2018 May; 15():253-265. PubMed ID: 29291545
[TBL] [Abstract][Full Text] [Related]
7. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
8. Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest.
Zhu L; Zhao L; Wang H; Wang Y; Pan D; Yao J; Li Z; Wu G; Guo Q
Toxicol Lett; 2013 May; 219(2):107-15. PubMed ID: 23470866
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor compound RY10-4 suppresses multidrug resistance in MCF-7/ADR cells by inhibiting PI3K/Akt/NF-κB signaling.
Yang X; Ding Y; Xiao M; Liu X; Ruan J; Xue P
Chem Biol Interact; 2017 Dec; 278():22-31. PubMed ID: 28987325
[TBL] [Abstract][Full Text] [Related]
11. A mathematical model of doxorubicin penetration through multicellular layers.
Evans CJ; Phillips RM; Jones PF; Loadman PM; Sleeman BD; Twelves CJ; Smye SW
J Theor Biol; 2009 Apr; 257(4):598-608. PubMed ID: 19183560
[TBL] [Abstract][Full Text] [Related]
12. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
13. A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression.
De U; Chun P; Choi WS; Lee BM; Kim ND; Moon HR; Jung JH; Kim HS
Int J Oncol; 2014 Jan; 44(1):167-76. PubMed ID: 24190517
[TBL] [Abstract][Full Text] [Related]
14. 3D cell culture systems modeling tumor growth determinants in cancer target discovery.
Thoma CR; Zimmermann M; Agarkova I; Kelm JM; Krek W
Adv Drug Deliv Rev; 2014 Apr; 69-70():29-41. PubMed ID: 24636868
[TBL] [Abstract][Full Text] [Related]
15. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
16. The O-methylation of chrysin markedly improves its intestinal anti-inflammatory properties: Structure-activity relationships of flavones.
During A; Larondelle Y
Biochem Pharmacol; 2013 Dec; 86(12):1739-46. PubMed ID: 24134915
[TBL] [Abstract][Full Text] [Related]
17. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma.
Dong H; Yang X; Xie J; Xiang L; Li Y; Ou M; Chi T; Liu Z; Yu S; Gao Y; Chen J; Shao J; Jia L
Biochem Pharmacol; 2015 Jan; 93(2):151-62. PubMed ID: 25522955
[TBL] [Abstract][Full Text] [Related]
18. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
19. A novel synthetic dibenzocyclooctadiene lignan analog XLYF-104-6 attenuates lipopolysaccharide-induced inflammatory response in RAW264.7 macrophage cells and protects BALB/c mice from sepsis.
Gu C; Yu FL; Yu L; He XY; Zhong D; He L; Lv L; Xie L; Liu S
Eur J Pharmacol; 2014 Apr; 729():22-9. PubMed ID: 24462571
[TBL] [Abstract][Full Text] [Related]
20. Reversal of P-glycoprotein-mediated multidrug resistance is induced by mollugin in MCF-7/adriamycin cells.
Tran TP; Kim HG; Choi JH; Na MK; Jeong HG
Phytomedicine; 2013 May; 20(7):622-31. PubMed ID: 23466342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
